Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.
You may also be interested in...
Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets
Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets
Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
Don’t Forget Injectable Insulin, Novo Nordisk Says
In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles